Lineage Cell Therapeutics Inc. — Director's Dealing 2016

Nov 17, 2016

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement (MM/DD/YYYY)			3. Issuer Name and Ticker or Trading Symbol
KNIGHT JAMES A.		10/19/2016			BIOTIME INC [BTX]
(Last) (First) (Middle)					4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
1010 ATLANTIC AVENUE, SUITE 102	_____ Director	___ X ___ Officer (give title below)		Sr VP, Head of Corporate Dev /	_ 10% Owner ___ Other (specify below)
(Street) ALAMEDA, CA 94501 (City) (State) (Zip)		5. If Amendment, Date Original Filed (MM/DD/YYYY)			_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person		6. Individual or Joint/Group Filing (Check Applicable Line)
					Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares, no par value				17036		D
Table II - Derivative Securities Beneficially Owned ( e.g.							, puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Shares	Amount or Number of	Security	Direct (D) or Indirect (I) (Instr. 5)

Explanation of Responses:

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% OwnerOfficer
KNIGHT JAMES A.
1010 ATLANTIC AVENUE		Sr VP, Head of Corporate Dev
SUITE 102
ALAMEDA, CA 94501

Signatures

/s/James A. Knight 11/16/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.